Diabetes Drug R&D Services ace

Inquiry

* First Name
* Last Name
* Business Email
Phone
Company/Institution
Job Title
* Services or Products of Interest ACRP30-Targeted Antidiabetic Drug Development Services
When do you expect your project to start?
Project Description
* All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
* Tick to confirm the Research Use Only (RUO) statement.

ACRP30-Targeted Antidiabetic Drug Development Services

ACRP30 (adiponectin), a key hormone secreted by adipocytes, plays a central role in regulating insulin sensitivity, suppressing inflammation, and improving glucose and lipid metabolism, making it a highly promising target for antidiabetic drug development. Ace Therapeutics provides preclinical professional services covering targeted ACRP30 drug development. From target mechanism studies and high-throughput screening of ACRP30 agonists/modulators, to structure optimization and efficacy validation, to preclinical pharmacokinetic and safety evaluations, we help our clients accelerate the development of innovative drug candidates.

ACRP30 as A Potential Antidiabetic Drug Target

Research indicates that serum protein ACRP30 (adiponectin) plays a key role in the pathophysiology of metabolic disorders, while TNF-α serves as a primary pro-inflammatory mediator contributing to insulin resistance. Studies further demonstrate that reduced ACRP30 levels are observed in numerous obesity and diabetes models due to elevated TNF-α, revealing an inverse correlation between this protein and diabetes. Notably, ACRP30-deficient mice develop insulin resistance leading to diabetes. Consequently, increased circulating ACRP30 levels enhance insulin sensitivity and improve glycemic control, establishing ACRP30 as a potential therapeutic target for diabetes.

ARCP30-mediated regulatory mechanisms in diabetic pathogenesis. Fig. 1 Role of ARCP30 in diabetes. (Dhankhar, S.; et al., 2023)

ACRP30 Targeted Antidiabetic Drug Development Services at Ace Therapeutics

Relying on its extensive experience in diabetes research, Ace Therapeutics has established a comprehensive preclinical development platform that can significantly accelerate our clients' antidiabetic drug development process.

Services	Description
Target validation and mechanism elucidation	Expression and functional analysis of ACRP30 and its receptors (AdipoR1/AdipoR2). Assessment of the activation effects of AMPK and PPAR-α signaling pathways. Adipocyte differentiation and insulin sensitivity association study.
ACRP30 agonist development	Small molecule agonist screening: High-throughput virtual screening and in vitro validation based on ACRP30 receptor structure. Protein mimetic design: Development of ACRP30 analogs or receptor agonist antibodies. Peptide agonist optimization: Enhancement of stability and bioactivity through structural modification.
In vivo and in vitro functional validation	In vitro model Adipocyte glucose uptake assay. Assessment of hepatocyte glycogen synthesis and gluconeogenesis inhibition. In vivo model ob/ob mice: assessment of compound efficacy in reversing obesity-induced insulin resistance. High-fat diet (HFD)-induced model: verifying drug effects on metabolic syndrome. db/db mice: Evaluating the long-term efficacy and β-cell protective effect.
Preclinical safety assessment	Dynamic monitoring of changes in body weight, food intake and body composition. Pathologic evaluation of liver and muscle lipid deposition. Specialized testing for cardiovascular safety (e.g., blood pressure, heart rate).

Advantages of ACRP30-Targeted Antidiabetic Drug Development Services

One-stop drug development services: We provide one-stop service for the whole process from drug discovery, preclinical research to clinical trial filing.
Mature ACRP30 research platform: ACRP30 overexpression/knockdown cell models and transgenic animals are available.
Integrated multi-omics analysis: Combining metabolomic, proteomic and transcriptomic data to comprehensively analyze drug mechanism.

Ace Therapeutics utilizes our expertise in diabetes animal models and preclinical development to provide comprehensive services including ACRP30 agonist screening, functional validation, efficacy evaluation, and safety analysis to help you accelerate your innovative drug discovery process. Please feel free to contact our expert team for customized service solutions or project cooperation details. We will provide you with professional technical support and efficient project solutions to jointly promote the development of antidiabetic drugs targeting ACRP30.

Reference

Dhankhar, S.; et al. Novel targets for potential therapeutic use in Diabetes mellitus. Diabetology & Metabolic Syndrome. 2023, 15(1): 17.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services